Bitcoin Generation Inc. (BTGN)

[mrpenny2000]

InoLife Technologies, Inc. to Market a Plavix Metabolizing Test to
the Medical Industry


RALEIGH, NC -- (MARKETWIRE) -- 09/01/10 --

InoLife Technologies, Inc. (OTCBB: INOL), a service based healthcare products
development, integration and marketing Company, announced today it will provide
and market a proprietary metabolizing test to physicians and practitioners to
identify how a patient's genetic makeup may affect the body's response to
Plavix (colpidogrel). The test will only be made available to physicians.

The Food and Drug Administration recently announced that Plavix must now
carry a so-called "black box" warning label after a landmark study revealed
that patients who were "non-responders" as a result of a genetic variation were
"3.58 times more likely to have a fatal stroke or myocardial infarction."

Plavix, an $8-billion-a-year drug and considered to be the second best
selling drug in the world, reduces the risk of heart attack, stroke, and
cardiovascular death in patients with cardiovascular disease by making
platelets less likely to form blood clots. Plavix does not have its
anti-platelet effects until it is metabolized into its active form by the liver
enzyme, CYP2C19.

"We determined that there are three critical problems that can lead to a
level of non-response to Plavix," said Dr. Frederic J. Vagnini, M.D., FACS, a
board certified cardiovascular surgeon who, after more than 20 years of
performing heart surgery, has turned his clinical practice to the prevention of
heart and related diseases. "First, in anyone an abnormality may be present
within a gene abbreviated as CYP2C19 (and other variants) which significantly
increases the risk of stroke or death due to clotting failure. Second, there
are different variants or mutations between ethnic groups; some studies have
indicated that one in three Caucasians and 40% of Asian of African-American
populations have this abnormality.

"Among clinicians there have been discussions centering on differing dosing
approaches. Perhaps the most important result of InoLife's DNA test is that
each patient will be able to have an individually tailored course of treatment
since some require longer periods on it," Vagnini stated.

InoLife Technologies feels that this is an important test for those who take
Plavix or who may need to take Plavix in the future. The Company is very
pleased that by addressing the black box warning, those who can be helped by
this medication will be.

InoLife's Plavix Metabolizing Test is only available to physicians and
medical professionals. It is not available for home use. Please ask your
physician.

(Plavix is a trademark of Bristol-Myers Squibb/Sanofi Pharmaceuticals
Partnership.)

About InoLife Technologies, Inc Positioned for growth and success in a
burgeoning market, InoLife Technologies, www.inolifetech.com, is primarily
focused on products, services and solutions that will enable state-of-the-art
healthcare for today and the future for a diverse base of customers and
end-users. The Company's mission is to identify, develop, integrate and bring
to market innovative healthcare-based products and services that provide timely
and practical solutions for both humans and companion animals. The primary
products and services that InoLife is currently addressing focuses upon those
specific products and services that provide key solutions through the
innovative use of specific DNA testing and Genetic analysis systems.

The principal customers of InoLife's products and services are healthcare
providers, physicians, practitioners, hospitals, outpatient facilities and
veterinarians. Emphasis is being placed on individuals with a direct need for
the DNA testing solutions. InoLife will be marketing and distributing its
proprietary products to a wide variety of customers through e-commerce, direct
sales, healthcare providers, distributors and retail sellers including
pharmacies, specialty retailers and drugstores.

Forward-Looking Statements Safe Harbor Statement under the Private
securities Litigation Reform Act of 1995: The statements contained herein,
which are not historical, are forward-looking statements that are subject to
risks and uncertainties that could cause actual results to differ materially
from those expressed in the forward-looking statements including, but not
limited to, certain delays beyond the Company's control with respect to market
acceptance of new technologies, products and services, delays in testing and
evaluation of products and services, and other risks detailed from time to time
in the Company's filings with the Securities and Exchange Commission.

Contact: Henry Harrison IR Pro, 2.0, Inc. 407-862-5151
[e-mail] www.irprpro.com

Click here to go to Dow Jones NewsPlus, a web front page of today's most
important business and market news, analysis and commentary:
http://www.djnewsplus.com/nae/al?rnd=osCpnGHqDrYg4OGMQohjpA%3D%3D. You can use
this link on the day this article is published and the following day.


(END) Dow Jones Newswires

09-01-10 0845ET

08:45 090110